Claremont Creek Ventures portfolio company Gene Security Network (GSN) achieved a technical breakthrough that even Dear Abby can crow about. Never before, have scientists and clinicians been about to measure fetal DNA in a pregnant woman’s blood with enough accuracy to determine paternity or relevant information about the baby in utero — until now. If you are curious why this service might be helpful, see Dear Abby’s recent column below.
In . . .
→ Read full post: Why Dear Abby loves this company (and you should, too)
